医学
载脂蛋白B
动脉粥样硬化性心血管疾病
剩余风险
生命银行
内科学
危险系数
风险因素
胆固醇
比例危险模型
观察研究
心脏病学
内分泌学
低密度脂蛋白胆固醇
疾病
队列
队列研究
低风险
弗雷明翰风险评分
风险评估
流行病学
载脂蛋白E
作者
Allan D. Sniderman,Karol Mateusz Pencina,George Thanassoulis,Line Dufresne,Michael J. Pencina
标识
DOI:10.1093/eurjpc/zwag400
摘要
BACKGROUND: Apolipoprotein B (apoB) is the most accurate causal lipid factor associated with increased risk of atherosclerotic cardiovascular disease (ASCVD). While high HDL cholesterol has been considered protective, HDL-C-raising therapies have not shown benefit. OBJECTIVE: To assess whether HDL-C provides independent information from apoB and whether HDL-C modifies the effect of apoB on ASCVD risk. METHODS: 293,872 UK Biobank participants aged 37-73, free of CVD, not on lipid-lowering medication, and with complete standard risk factor data were followed for 10 years for incident ASCVD. Cox proportional hazard models, adjusted for standard risk factors, including log-triglycerides, used apoB and HDL-C residuals (regressed on each other) as primary exposures. Interaction between apoB and HDL-C was tested separately. RESULTS: When HDL-C residual was added to a model with apoB, both were significant: HRs per 1 SD were 1.16 (95% CI: 1.15-1.18; p < 0.001) for apoB and 0.85 (95% CI: 0.84-0.87; p < 0.001) for HDL-C residual. Similarly, adding apoB residual to a model with HDL-C yielded HRs of 1.14 (95% CI: 1.12-1.16; p < 0.001) for apoB residual and 0.84 (95% CI: 0.82-0.85; p < 0.001) for HDL-C. The apoB-HDL-C interaction was significant: HR 0.95 (95% CI: 0.93-0.96; p < 0.001), consistent across sexes. CONCLUSIONS: High HDL-C is associated with lower ASCVD risk, independent of apoB, and it attenuates the effect of high apoB on ASCVD risk. These findings suggest HDL-C's role in primary ASCVD prevention warrants re-evaluation. However, findings from an observational study, such as this, do not establish causation.
科研通智能强力驱动
Strongly Powered by AbleSci AI